About TRUVADA for a PrEP Indication

TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. The following factors may help to identify individuals at high risk:

  • Has partner(s) known to be HIV-1 infected, or
  • Engages in sexual activity within a high prevalence area or social network and one or more of the following:
    • Inconsistent or no condom use
    • Diagnosis of sexually transmitted infections
    • Exchange of sex for commodities (such as money, shelter, food, or drugs)
    • Use of illicit drugs, alcohol dependence
    • Incarceration
    • Partner(s) of unknown HIV-1 status with any of the factors listed above

When prescribing TRUVADA for pre-exposure prophylaxis, healthcare providers must:

  • Prescribe TRUVADA as part of a comprehensive prevention strategy because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection
  • Counsel all uninfected individuals to strictly adhere to the recommended TRUVADA daily dosing schedule because the effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels
  • Confirm a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection
  • Screen for HIV-1 infection at least once every 3 months while taking TRUVADA for PrEP
  • Be sure to not prescribe TRUVADA for a PrEP indication if signs or symptoms of acute HIV-1 infection are present

Mechanism of action for pre-exposure prophylaxis

By inhibiting HIV-1 from replicating as it enters the body, TRUVADA for a PrEP indication helps prevent the virus from establishing permanent infection. TRUVADA for a PrEP indication does not replace existing HIV-1 prevention strategies.

The information on this site is intended for adult residents
of the United States.

Close the layer

You Are Now Leaving

By following this link, you are now leaving www.TRUVADApreprems.com.
These sites are not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for their content or your use of them.